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Abstract 
Microtubule associated protein tau is abnormally phosphorylated in Alzheimer disease (AD) brain. In the present study we investigated (i) whether 
tau is axonal or both axonal and somatodendritic, (ii) whether tau is a marker of Alzheimer neurofibrillary pathology, and (iii) whether the levels 
of tau in the cytosol (100,000 x g supernate) from AD brain are altered. Frozen autopsied tissue from 20 AD, 17 normal aged and 15 neurological 
control cases obtained 3-8 h postmortem were analyzed. Levels of normal, total, and abnormally phosphorylated tau were determined by a 
radioimmunoslot-blot assay using mAb Tau-1 as the primary antibody. Both frontal gray matter homogenate and cytosol from normal brains had 
3&45% higher levels of normal tau than the corresponding fractions from the white matter. In AD frontal and temporal cortices, the total tau levels 
were 6- to 7-fold higher than in cerebellar cortex (P < 0.01 and P < 0.02). Furthermore, tau levels of cerebellar cortex, an area of the brain unaffected 
with Alzheimer neurofibrillary changes, were indistinguishable between AD and control groups. The levels of normal tau in cytosol from both frontal 
gray and white matters in AD were reduced by approximately 40% (P < 0.05). The levels of total tau in AD frontal and temporal cortex were 4- 
to 5-fold higher than in the corresponding tissue from control cases (P < 0.01) and this increase was in the form of abnormally phosphorylated tau. 
These studies suggest (i) that there is probably at least as much tau in the somatodendritic compartment as in the axonal compartment, (ii) that the 
abnormally phosphorylated tau is a biochemical marker of the neurofibrillary pathology in AD, and (iii) that the levels of normal tau are significantly 
reduced in the 100,000 x g brain supernate from AD cases. 
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1. Introduction 
Tau is one of the major microtubule associated pro- 
teins of a normal mature neuron in the brain. In human 
brain six isoforms of tau have been identified and these 
isoforms are the products of alternate splicing of a single 
tau gene [l]. Tau promotes the microtubule assembly 
from the tubulin subunits and stabilizes the formed mi- 
crotubules [2,3]. Tau is a phosphoprotein and the degree 
of phosphorylation determines its microtubule polymer- 
izing activity. The in vitro phosphorylated tau does not 
promote the microtubule assembly [4]. 
Normal tau contains 2-3 mol of phosphate per mol of 
the protein. In Alzheimer disease (AD) brain tau is ab- 
normally hyperphosphorylated [5-81. The abnormal tau 
from AD brain, which contains 5-9 mol of phosphates 
per mol of the protein [LX], does not promote the microtu- 
bule assembly [6,9,10]. One of the histopathological hall- 
marks of Alzheimer disease (AD) is the presence of 
paired helical filaments (PHF) in selected neurons in the 
neocortex, especially the hippocampus, and the degree of 
these neurofibrillary changes correlates with the severity 
of dementia in the afflicted patients [11,12]. Accumula- 
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tions of the PHF in the affected neurons are seen in the 
cell body as neurofibrillary tangles, in dystrophic 
neurites in the neuropil as neuropil threads [13], and in 
dystrophic neurites surrounding a core or wisp of ex- 
tracellular B-amyloid in neuritic (senile) plaques. The 
microtubule associated protein tau in abnormally hyper- 
phosphorylated form is the major protein subunit of 
PHF [5,7,14,15]. In addition to PHF, there is a signifi- 
cant pool of soluble abnormally phosphorylated tau in 
AD brain [8]. We have previously reported that the levels 
of total tau in frontal cortex homogenates were several- 
fold higher in AD than in control cases and this increase 
was in the form of the abnormally phosphorylated tau 
[161. 
The present study was undertaken to examine: (i) 
whether tau is only axonal or also somatodendritic in 
distribution; (ii) whether the abnormally phosphorylated 
tau is a biochemical marker of neurofibrillary pathology 
in AD brain; and (iii) whether the levels of tau are altered 
in AD brain cytosol. 
2. Materials and methods 
Monoclonal antibody Tau-I [I71 was generously supplied by Dr. L.I. 
Binder, Molecular Geriatrics, Lake Bluff, IL, USA. Tau-1 is a phos- 
phate-dependent antibody to a non-phosphorylated epitope of tau in- 
volving Ser’W/Ser*“2 (of human tau,,). The abnormally phosphorylated 
tau from AD brain which is phosphorylated at Ser’99 and/or Se? is 
recognized by Tau-1 only after these sites are dephosphorylated; alka- 
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line phosphatase is one of the phosphatases that can dephosphorylate 
the abnormal tau at the Tau-l-site 151. ‘ZSI-labeled antibody to mouse 
IgG was purchased from Amersham (Arlington Heights, IL, USA). 
Alkaline phosphatase was obtained from Boehringer Mannheim (Indi- 
anapolis, IN, USA). 
2.1. Tissue used, preparation of brain homogenates and cytosols, and 
protein assays 
AD and control brains obtained between 2 and 8 h postmortem and 
stored frozen at -75°C were used for this study. The AD cases were 
histopathologically confirmed, and the controls were age-matched. 
Frontal cortex from fourteen AD, eleven neurological controls, and 
nine normal controls, and temporal cortex from ten cases each of AD 
and neurological controls, and seven normal controls cases were as- 
sayed for the levels of normal and abnormally phosphorylated tau. 
Cerebellar cortex from five AD and four cases each from normal and 
neurological control groups were also analyzed for the tau levels in the 
homogenates. Approximately l-2 g was chiselled off from the frozen 
tissue, thawed and cleaned off the meninges. Gray matter was separated 
from the white matter at 4”C, and each tissue was homogenized (20% 
w/v homogenate) by 20 strokes in a glass-Teflon homogenizer at 4°C 
in 10 mM Tris, pH 7.2, containing 1 mM each of EDTA and EGTA 
and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). An aliquot was 
saved and the rest was centrifuged at 100,000 x g using Beckman TLA- 
45 rotor for 10 min at 4°C. Homogenates and supernatants were kept 
frozen at -75°C in aliquots until used. The protein concentrations of 
the tissue fractions were determined by the method of Lowry et al. [18] 
as modified by Bensadoun and Weinstein [19]. 
2.2. Radioimmunoslot-blot assay for normal and abnormally 
phosphorylared tau 
Levels of normal and abnormally phosphorylated tau were deter- 
mined by a radioimmunoslot blot assay described previously [16]. 
Briefly, 1 pg total protein/250 ~1 of 50 mM Tris, pH 7.6, and 200 mM 
NaCl (TBS) and a cocktail of protease inhibitors (0.15 ,ffM aprotonin, 
1 PM leupeptin, and 1 PM pepstatin A) and phosphatase inhibitors 
(1 mM Na9V0, and 5 mM NaF) was applied in two sets of triplicates 
to a nitrocellulose membrane containing seventy-two slots and ad- 
sorbed by employing a moderate vacuum. After blocking with 5% 
bovine serum albumin (BSA)-TBS, the membrane was cut into two sets, 
one was treated at 37°C for 18 h with alkaline phosphatase (Boehringer 
Mannheim, Indianapolis, IN, USA) in 0.1 M Tris pH 8.0, containing 
the protease inhibitors aprotonin (0.3 PM), leupeptin (10 PM), pep- 
statin A (1.43pM) and phenylmethylsulfonyl fluoride (1 PM), while the 
other set was incubated in the same cocktail without alkaline phosphat- 
ase. These blots were then blocked with 5% BSA in phosphate-buffered 
saline, incubated with 1:25,000 diluted anti-tau mAb, Tau-1 [17] for 16 
h at room temperature, washed to remove excess antibody and incu- 
bated with I5 ml of 1% BSA, 0.05% Tween-20 in TBS containing 
‘ZSI-labeled antibody to mouse IgG (Amersham, Arlington Heights, IL, 
USA) at 0.05 ,&ml (13-2OpCi@g), for 2 h at room temperature. After 
washing with PBS-Tween-20, the slots were cut from the membrane and 
counted with 3 ml of Gammascint (National Diagnostics, Somerville, 
NJ, USA) per strip. 
Fresh bovine brains were used to isolate tau [14] which was used as 
the standard in concentrations between 0 and 10 ng/pg BSA. For 
homogenates 0.35 pg and 1 pg and for cytosolic fractions I pg protein 
per slot were applied. 
3. Results 
3.1. Distribution of normal tau in frontal white and gray 
matter 
The normal tau levels in both frontal and temporal 
gray matter homogenates were highest in AD and lowest 
in the neurological controls (Fig. 1, F/GH and T/GH). 
The differences in the tau levels between the AD and the 
neurological controls were statistically significant 
(P c 0.05), whereas those between AD and the normal 
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Fig. 1. Normal tau levels in brain white and gray matters. Tau levels 
were determined in homogenates of gray and white matter and the 
100,000 x g supernate fractions from AD and control brains by radio- 
immunoslot blot assay using the monoclonal antibody Tau-1 as the 
primary antibody as described in section 2. The bar diagram shows 
mean f S.E.M. of each group and the number of cases analyzed are in 
parenthesis. AD: Alzheimer disease; NA: Normal aged controls; NC: 
Neurological controls; F, Frontal; T, Temporal; Cb, Cerebellum; G, 
Gray matter; W, White matter; H, Homogenate; and S, 100,000 x g 
Supernate. 
aged groups were insignificant. In frontal white matter 
similar but insignificant differences between the three 
groups were observed (Fig. 1, F/WH). In cerebellar cor- 
tex homogenate there were no significant differences in 
the levels of normal tau among the three groups (Fig. 1, 
Cb/GH). A comparison of the tau levels in each group 
between the gray and the white matter homogenates, 
representing somatodendritic and axonal compartments, 
respectively, revealed no significant differences in the 
number of cases studied, although all the tau values were 
2CL60% higher in the gray matter than the white matter 
(Fig. 1, compare F/GH with F/WH). 
Unlike tau levels in the whole tissue homogenate, the 
cytosolic normal tau levels in frontal gray matter were 
approximately 40% lower in AD as compared to normal 
(P < 0.05) and neurological controls (P < 0.01). Simi- 
larly, the normal tau levels in white matter cytosol from 
AD cases were also found to be approximately 40% 
lower than the identically treated normal (P - 0.05) and 
the neurological control cases (P < 0.001) . The differ- 
ences in tau levels between gray and white matter cy- 
tosols were found to be insignificant in all the three 
groups of cases. 
3.2. Distribution of abnormally phosphorylated tau in 
affected and unaffected regions of AD brain 
Histopathologically neurofibrillary degeneration is ex- 
tensive in the neocortex whereas the cerebellar cortex is 
practically uninvolved in AD brain. In order to learn the 
association of the abnormal phosphorylation of tau with 
the neurofibrillary changes, the levels of abnormally 
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phosphorylated tau and as an internal control of normal 
tau were determined in frontal and temporal cortices 
representing the affected areas and the cerebellar cortex 
as the unaffected area of the AD brain. As a control, the 
levels of the normal and the abnormally phosphorylated 
tau were also determined in neurological and normal 
aged control brains. The normal tau levels in the frontal 
and temporal gray matter homogenates were similar to 
that of the cerebellar cortex in the two control groups, 
whereas in AD cases the levels of normal tau in frontal 
and temporal cortices were significantly greater 
(P < 0.05) than the cerebellar cortex (Fig. 1, compare 
FlGH and T/GH with CWGH). The abnormally 
phosphorylated tau levels both in AD temporal and 
frontal cortex were several-fold higher than in cerebellar 
cortex (Fig. 2; T/GH vs. Cb/GH: P c 0.05; F/GH vs. 
CWGH: P c 0.01); the cerebellar cortex which is unaf- 
fected with neurofibrillary pathology in AD had unde- 
tectable levels of the abnormal tau (Fig. 2; CWGH). 
Furthermore, the levels of total tau in the frontal and 
temporal cortex homogenates were several-fold higher in 
AD than the control cases and this increase was largely 
in the form of the abnormally phosphorylated tau (see 
Figs. 1 and 2). These data suggested that the levels of 
abnormally phosphorylated tau are associated to the his- 
topathology of the disease. 
F/WH F/GH T/GH Cb/GH 
Fig. 2. Levels of abnormally phosphorylated tau in AD and control 
brains. As described in section 2 the abnormally phosphorylated tau 
levels were determined as a difference between total tau and normal tau 
levels. The total tau and normal tau levels were determined by Tau-I 
antibody by radioimmunoslot-blot assay with and without pretreat- 
ment of the blot with alkaline phosphatase respectively. Rest of the 
details are the same as in Fig. 1. 
A comparison of abnormally phosphorylated tau lev- 
els between the frontal gray matter and the white matter 
supernates demonstrated consistently higher average 
values in the white matter in all the groups (Fig. 3). The 
abnormally phosphorylated tau levels were 0.07-0.17 ng/ 
,ug cytosolic protein in gray matter and 0.1 l-O.49 ng/,ug 
protein in white matter cytosol. However, the differences 
were not statistically significant in the number of cases 
studied. Similarly among the three groups, apparently 
higher values of abnormally phosphorylated tau were 
observed in AD cases, though without any significant 
difference from the control groups. 
brillary degeneration, it is critical to learn the cellular 
distribution of this protein quantitatively in normal 
brain and in affected and non-affected areas of AD 
brain, Based on immunocytochemical studies tau was 
previously reported to be mainly an axonal protein [ 171 
and was suggested to be misdirected from the axonal to 
the somatodendritic ompartment in neurons with neu- 
rofibrillary pathology in AD [20]. Employing a quantita- 
tive immunoassay the present study demonstrates (i) that 
there is at least as much tau in the somatodendritic om- 
partment as in the axonal compartment in normal 
human brain; (ii) that abnormally phosphorylated tau is 
a biochemical marker of Alzheimer neurofibrillary pa- 
thology and the neurofibrillary changes are several-fold 
greater in the somatodendritic compartment than the 
axonal compartment; and (iii) that in 100,000 x g super- 
nates of AD neocortex there is an approximately 40% 
decrease in the levels of normal tau. 
4. Discussion 
To understand the role of tau in Alzheimer neurofi- 
Table 1 
Summary of cases used 
Diagnosis Age (years) Sex PM1 (hours) 
mean f S.E.M. M/F mean f S.E.M. 
AD (20) 73 f 3 8/12 4.2 f 0.3 
NA (17) 72 f 6 918 5.7 f 1.1 
NCb (15) 81 +3 11/4 3.8 f 0.3 
AD: Alzheimer disease; NA: normal aged controls; NC: neurological 
controls; PMI: postmortem interval. “Number of cases. b5 cases of 
Parkinson’s disease, ? cases of Lewy body disease, 3 cases of Multi- 
infarct dementia, 1 case of Huntington disease and 4 cases of unknown 
diagnosis. 
Immunocytochemistry of normal tau is problematic 
because it is very sensitive to fixatives and the conditions 
of fixation (see [17,21]). This problem has lead to earlier 
studies reporting that tau is axonal [17,20,22]. Subse- 
quent immunocytochemical and in situ hybridization 
studies also showed the presence of tau in the somato- 
dendritic compartment of normal mature neurons 
[23,24]. Since the axonal volume in grey matter is a very 
small fraction of that in the white matter, and the white 
matter contains very few neuronal cell bodies, the grey 
matter and the white matter are representative of the 
somatodendritic and the axonal pools, respectively. In 
the present study, employing a quantitative radio-immu- 
noassay we have found that there is 3045% more tau in 
normal brain gray matter than in the white matter, al- 
though because of the biological scatter the differences 
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Fig. 3. Levels of abnormally phosphorylated tau in frontal gray and 
white cytosols from AD and control cases. Abnormally phosphorylated 
tau levels were determined in 100,000 x g supematants of frontal gray 
and white matter homogenates from AD, and control groups. Rest of 
the details are the same as in Figs. 1 and 2. 
in the number of brains examined were not statistically 
different. The statistically insignificant increase in nor- 
mal tau in gray matter over white matter was observed 
both in tissue homogenates as well as in the cytosols. 
These findings suggest hat there is at least as much tau 
in the somatodendritic compartment as in the axonal 
compartment. Some of the tau measured in total tissue 
homogenate can also be of glial origin, since tau has been 
observed immunocytochemically in oligodendrocytes 
and astroglia [23,25]. However, given the larger propor- 
tions of gila in white matter than gray matter, it is un- 
likely that there is a significantly greater contribution of 
glial tau in gray matter than white matter. 
The levels of abnormally phosphorylated tau corre- 
sponded to the known topography of neurofibrillary pa- 
thology in AD. In AD brains the levels of abnormally 
phosphorylated tau were several-fold greater in frontal 
and temporal cortices than the cerebellar cortex; cerebel- 
lar cortex is known to be minimally affected with neu- 
rofibrillary changes in AD [26]. Most of the abnormally 
phosphorylated tau in AD brain was sedimentable. Less 
than 1% of the abnormal tau in homogenate from AD 
frontal cortex was recovered in the cytosol (taking cy- 
tosol as 20% of total tissue protein) from the same. In 
contrast, the levels of the abnormal tau in cytosol from 
frontal white matter were several-fold greater than in the 
corresponding gray matter and approximately 4% (tak- 
ing cytosol as 20% of total tissue protein) of the white 
matter abnormal tau was not sedimentable. Taken to- 
gether, these studies suggest (i) that the abnormally 
phosphorylated tau is a biochemical marker of Alz- 
heimer neurofibrillary pathology and (ii) that in AD the 
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abnormal tau in the cerebral white matter might be dif- 
ferent from that in the corresponding gray matter. The 
nature of these differences is, at present, not known. It 
is possible that the white matter abnormal tau is less 
hyperphosphorylated than that in the gray matter. 
The levels of normal tau in the frontal gray matter and 
white matter homogenates from AD were approximately 
two-fold greater than the neurological controls and only 
slightly higher than the normal aged cases. The levels of 
normal tau in cerebellar cortex from AD and both nor- 
mal and neurological control groups were similar. These 
studies suggest hat there is no decrease in the levels of 
normal tau in AD brains, and that there might be a slight 
increase in the areas of AD brain affected with neurofi- 
brillary pathology. 
Unlike brain homogenate, the cytosol (i.e. 100,000 x g 
supernate) prepared from the same had approximately 
40% lesser normal tau in AD than normal controls in 
both frontal gray matter and white matter. This pattern 
of decrease in normal tau in the cytosol was specific to 
AD because in the neurological control group the pat- 
tern was opposite. A recent study has shown that in AD 
brain, the normal tau binds to the abnormally 
phosphorylated tau co-sedimenting with the latter [lo]. 
The decrease in the normal tau in cytosol from AD brain 
observed in the present study, is probably due to the 
binding of normal tau to the soluble abnormally 
phosphorylated tau and sedimenting at 100,000 x g dur- 
ing the isolation of the cytosol. 
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